Viewing Study NCT05959356

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:37 PM
Ignite Modification Date: 2026-05-17 @ 9:39 AM
Study NCT ID: NCT05959356
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2023-07-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
Sponsor: Sun Yat-sen University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Colorectal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None First-line treatment View
None RAS/BRAF wild-type View
None Microsatellite stable(MSS) View
None Unresectable left-side metastatic colorectal cancer View
None Envafolimab View